The Investigators plan to study the innate and adaptive immune response, the inflammatory response, and associated complications such as complement activation and neurological damage in SARS-Cov-2 infected individuals. Patients with mild, moderate and severe COVID-19 disease will be enrolled.
The severity of coronavirus disease 2019 (COVID-19) ranges from asymptomatic infection to
severe illness requiring mechanical ventilation. Immunological factors which lead to severe
disease in certain COVID-19 patients remain incompletely understood. Neurological damage and
complement activation may be a consequence of excess inflammation in severe COVID-19. The
investigators plan to study the innate and adaptive immune response and potentially
associated complications such as neurological damage and complement activation in mild,
moderate and severe COVID-19 courses.
Other: Analysis of cytokine response, innate and adaptive immune response, complement activation, and serum neurofilaments as a marker of neurological damage.
Analysis of cytokine response, innate and adaptive immune response, complement activation, and serum neurofilaments as a marker of neurological damage.
Inclusion Criteria:
- PCR confirmed SARS-Cov-2 infection
Exclusion Criteria:
- Refusal to participate
- Age < 18 years
Bern University Hospital
Bern, Switzerland